ORAL ACYCLOVIR IN NEONATAL HERPEX SIMPLEX

口服阿昔洛韦治疗新生儿单纯疱疹

• 批准号: 7380396
• 负责人: DAVID W KIMBERLIN
• 金额: $ 0.42万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380396
• 关键词: ORAL; ACYCLOVIR; NEONATAL; HERPEX; SIMPLEX

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This protocol evaluates the use of 6 months suppressive oral acyclovir therapy in neonates following herpes simple virus disease limited to the skin, eye, and mouth. This is a double-blind, randomized study. Following 14 days of IV acyclovir, neonates will be randomized to receive suppressive acyclovir or to receive identically flavored placebo for a period of six months. Cutaneous HSV recurrences in either group will be treated with open label oral acyclovir.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。该方案评估了6个月抑制性口服阿昔洛韦治疗仅限于皮肤、眼睛和口腔的单纯疱疹病毒病新生儿的使用情况。这是一项双盲随机研究。在静脉注射阿昔洛韦14天后，新生儿将随机接受抑制性阿昔洛韦或相同口味的安慰剂，为期6个月。无论哪一组的皮肤HSV复发，都将用开放标签口服阿昔洛韦治疗。